Concord Biotech Limited (BOM:543960)

Market Cap	167.18B
Revenue (ttm)	11.92B
Net Income (ttm)	3.56B
Shares Out	n/a
EPS (ttm)	34.03
PE Ratio	46.95
Forward PE	34.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,224
Average Volume	6,301
Open	1,803.60
Previous Close	1,699.90
Day's Range	1,624.65 - 1,803.60
52-Week Range	1,370.05 - 2,658.00
Beta	n/a
RSI	26.51
Earnings Date	Aug 13, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,377
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543960

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.